Open AccessPragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I‐PICC) Study
Author(s) -
Brunette Charles A.,
Miller Stephen J.,
Majahalme Nilla,
Hau Cynthia,
MacMullen Lauren,
Advani Sanjay,
Ludin Sophie A.,
Zimolzak Andrew J.,
Vassy Jason L.
Publication year - 2020
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12723
Subject(s) - generalizability theory , pharmacogenetics , medicine , clinical trial , psychological intervention , personalized medicine , medline , precision medicine , clinical study design , pharmacogenomics , alternative medicine , family medicine , bioinformatics , psychology , nursing , pharmacology , pathology , genetics , developmental psychology , biology , political science , genotype , law , gene
Pragmatic clinical trials (PCTs) have an established presence in clinical research and yet have only recently garnered attention within the landscape of genomic medicine. Using the PRagmatic‐Explanatory Continuum Indicator Summary 2 (PRECIS‐2) as a framework, this paper illustrates the application of PCT principles to The Integrating Pharmacogenetics In Clinical Care (I‐PICC) Study, a trial of pharmacogenetic testing prior to statin initiation for cardiovascular disease prevention in primary care. The trial achieved high engagement with providers (85% enrolled of those approached) and enrolled a representative sample of participants for which statin therapy would be recommended. The I‐PICC Study has a high level of pragmatism, which should enhance the generalizability of its findings. The PRECIS‐2 may be useful in the design and evaluation of PCTs of genomic medicine interventions, contributing to the generation of evidence that can bridge the gap between genomics innovation and clinical adoption.